Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Burns

Showing results (91-100 of 102) with videos related to

Pageof 11
Sort By:
Journal of Applied Physiology (Bethesda, Md. : 1985)|March 11, 2021
Time course and magnitude of ventilatory and renal acid-base acclimatization following rapid ascent to and residence at 3,800 m over nine daysJordan D Bird, Jack K Leacy, Glen E Foster, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.
Haematologica|June 19, 2025
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated <i>versus</i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationLin Li, Yishan Ye, Jacques-Emmanuel Galimard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
The New England Journal of Medicine|July 20, 2011
Prevention of HIV-1 infection with early antiretroviral therapyMyron S Cohen, Ying Q Chen, Marybeth McCauley, et al.
Pageof 11

Showing results (91-100 of 102) with videos related to

Sort By:
Pageof 11
Journal of Applied Physiology (Bethesda, Md. : 1985)|March 11, 2021
Time course and magnitude of ventilatory and renal acid-base acclimatization following rapid ascent to and residence at 3,800 m over nine daysJordan D Bird, Jack K Leacy, Glen E Foster, et al.
Ebiomedicine|January 25, 2021
Pharmacokinetics and predicted neutralisation coverage of VRC01 in HIV-uninfected participants of the Antibody Mediated Prevention (AMP) trialsYunda Huang, Logashvari Naidoo, Lily Zhang, et al.
The Lancet. HIV|June 5, 2020
Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trialRaphael J Landovitz, Sue Li, Joseph J Eron, et al.
Hemasphere|June 14, 2024
Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real-world intention-to-treat analysisMaeve A O'Reilly, William Wilson, David Burns, et al.
Haematologica|June 19, 2025
TET2 mutation does not impact the prognosis of adult acute myeloid leukemia patients receiving a hematopoietic stem cell transplantation in first remission: similar outcome following matched sibling and unrelated <i>versus</i> haploidentical donor transplants in a multi-center retrospective analysis from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow TransplantationLin Li, Yishan Ye, Jacques-Emmanuel Galimard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
A Phase 2b Study to Evaluate the Safety and Efficacy of VRC01 Broadly Neutralizing Monoclonal Antibody in Reducing Acquisition of HIV-1 Infection in Women in Sub-Saharan Africa: Baseline FindingsNyaradzo M Mgodi, Simbarashe Takuva, Srilatha Edupuganti, et al.
Plos Medicine|November 9, 2018
Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trialRaphael J Landovitz, Sue Li, Beatriz Grinsztejn, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 15, 2021
Feasibility and Successful Enrollment in a Proof-of-Concept HIV Prevention Trial of VRC01, a Broadly Neutralizing HIV-1 Monoclonal AntibodySrilatha Edupuganti, Nyaradzo Mgodi, Shelly T Karuna, et al.
Cancer Biology & Therapy|April 22, 2006
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cellsPhillip C C Liu, Xiangdong Liu, Yanlong Li, et al.
The New England Journal of Medicine|July 20, 2011
Prevention of HIV-1 infection with early antiretroviral therapyMyron S Cohen, Ying Q Chen, Marybeth McCauley, et al.
Pageof 11